Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fatty acids plus valproic acid for borderline personality disorder
ACTRN12612001150831Phase 4Not yet recruiting
- Sponsor
- Centre for Personality Disorders
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in borderline personality disorder (BPD) comparing Valproic acid with Omega-3 fatty acids plus valproic acid (2 arms). Primary endpoints: Global symptomatology at 12 weeks, Borderline personality disorder psychopathology at 12 weeks and 1 more. Planned start Nov 2012; status: not yet recruiting.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acidvalproic acid
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on ACTRN12612001150831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001150831.